DBV Technologies and Nestlé Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy
(Thomson Reuters ONE) -
Press Release
Montrouge, France, May 31, 2016
DBV Technologies and Nestlé Health Science Form Collaboration to Develop and
Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy
Collaboration will support DBV's Mission to Develop Transformational Product
Candidates for the Care of Pediatric Patients Suffering from Food Allergies
Under the Terms of the Agreement, DBV will Develop a Ready-To-Use Test to
Diagnose Allergy to Cow's Milk Protein
DBV is Eligible to Receive up to ?100 Million in Potential Development,
Registration and Commercial Milestones, while Granting Global Commercialization
Rights to Nestlé Heath Science
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
that it has entered into an exclusive global collaboration with Nestlé Health
Science for the development and, if approved, commercialization of MAG1C, an
innovative, ready-to-use and standardized atopy patch-test for the diagnosis of
Cow's Milk allergy (CMPA) in infants and toddlers.
By leveraging its proprietary Viaskin® technology platform, DBV will be
responsible for developing this new pharmaceutical product candidate, and if
approved by the appropriate regulatory agencies, Nestlé Health Science will
support its worldwide commercialization through its range of nutritional
solutions tailor-made for babies and young children suffering from CMPA and
other food allergies and intolerances.
DBV Technologies' Chairman and Chief Executive Officer, Dr. Pierre-Henri
Benhamou, said, "Improving the lives of those suffering from food allergies is
DBV's mission, and through this exciting partnership with Nestlé Health Science,
we are further extending our portfolio of potentially transformational and
cutting-edge products. Combining DBV's innovative and proprietary technology
with Nestlé Health Science's global presence and expertise in nutritional
therapies is a synergistic approach that we believe has the potential to improve
the overall health of our patients."
Greg Behar, CEO of Nestlé Health Science, said, "This innovation can become the
breakthrough diagnostic for CMPA. Early diagnosis and nutritional intervention
helps get infants happily back on the path of healthy development, alleviate the
anxieties of parents and reduce healthcare costs. Our reach in the field of
pediatric allergy makes Nestlé Health Science an ideal commercialization partner
for DVB's innovative diagnostic patch. This collaboration is another step in our
strategy of advancing the role of nutrition through science-based innovation."
Under the terms of the agreement, DBV will be eligible to receive up to ?100
million in development, registration and commercial milestones, including an
upfront payment of ?10 million. DBV will be responsible for performing
development activities up through a pivotal Phase III clinical program,
following which Nestlé Health Science has the exclusive right to commercialize
the product globally, if approved. DBV will pay for all development-related
costs of MAG1C, including a worldwide clinical program, as well as manufacturing
costs. If MAG1C is successfully manufactured by DBV, the company will receive a
supply price with a mark-up from Nestlé Health Science. In addition, Nestlé
Health Science will pay to DBV tiered royalties on global product sales. This
new diagnostic test is expected to be submitted for approval to regulatory
authorities worldwide by 2021.
CMPA is a difficult to diagnose condition that impacts up to 2-3%(1) of infants
and toddlers aged two and under during a critical stage of their development.
Amongst its range of nutritional therapies across a broad spectrum of health
conditions and ages, Nestlé Health Science already has a range of nutritional
solutions tailor-made for babies and young children with cow's milk protein
allergy and other food allergies/intolerances (Althéra®, Alfaré®, Alfamino®).
About DBV Technologies
DBV Technologies developed Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
About Nestlé Health Science
Nestlé Health Science, a wholly-owned subsidiary of Nestlé, is a health-science
company engaged in advancing the role of nutritional therapy to change the
course of health for consumers, patients and our partners in healthcare. Its
portfolio of nutrition solutions, diagnostics, devices and drugs, targets a
number of heath areas, such as inborn errors of metabolism, pediatric and acute
care, obesity care, healthy aging as well as gastrointestinal and brain health.
Through investing in innovation and leveraging leading edge science, we bring
forward innovative nutritional therapies with proven clinical, health economic
value and quality of life benefits. Nestlé Health Science employs around 3,000
people worldwide and is headquartered in Epalinges (near Lausanne), Switzerland.
For more information, please visit: www.nestlehealthscience.com.
Forward Looking Statements
This press release contains forward-looking statements, including statements
about the potential safety and efficacy of Viaskin for the diagnosis of CMPA and
the Company's development and commercialization plans for MAG1C. Forward-
looking statements are not promises or guarantees and involve substantial risks
and uncertainties. The Company's product candidates have not been approved for
sale in any jurisdiction. Among the factors that could cause actual results to
differ materially from those described or projected herein are uncertainties
associated generally with research, development and commercialization, clinical
trials and related regulatory reviews and approvals, the risk that historical
preclinical results may not be predictive of future clinical trial results, and
the risk that historical clinical trial results may not be predictive of future
trial results. A further list and description of these risks, uncertainties and
other risks can be found in the Company's regulatory filings with the French
Autorité des Marchés Financiers, the Company's Securities and Exchange
Commission filings and reports, including in the Company's Annual Report on Form
20-F for the year ended December 31, 2015 and future filings and reports by the
Company. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. DBV Technologies undertakes no obligation to update or revise the
information contained in this Press Release, whether as a result of new
information, future events or circumstances or otherwise.
References
(1). Høst A. Frequency of cow's milk allergy in childhood. Ann Allergy Asthma
Immunol 2002;89 (Sup1):33-7
DBV Technologies Contacts
Susanna Mesa
Senior Vice President, Strategy
Tel. : +1 212-271-0861
susanna.mesa(at)dbv-technologies.com
DBV Technologies Media Contacts US & Europe
Marion Janic Caroline Carmagnol
Rooney & Associates Alize RP - Relation Presse
Tel. : +1-212-223-4017 Tel. : +33(0)6 64 18 99 59
mjanic(at)rooneyco.com
caroline(at)alizerp.com
PDF Version:
http://hugin.info/156437/R/2016569/747952.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
[HUG#2016569]
Unternehmensinformation / Kurzprofil:
Datum: 31.05.2016 - 07:03 Uhr
Sprache: Deutsch
News-ID 474416
Anzahl Zeichen: 10344
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 268 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies and Nestlé Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
